Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 2046Neoplasms 1460Carcinoma, Non-Small-Cell Lung 1363Prostatic Neoplasms 1106Multiple Myeloma 872Leukemia, Myeloid, Acute 772Colorectal Neoplasms 713Neoplasm Metastasis 704Lung Neoplasms 697Melanoma 688Lymphoma 666Leukemia 596Lymphoma, Non-Hodgkin 593Leukemia, Lymphocytic, Chronic, B-Cell 535Ovarian Neoplasms 535Pancreatic Neoplasms 500Precursor Cell Lymphoblastic Leukemia-Lymphoma 485Recurrence 474Myelodysplastic Syndromes 425Lymphoma, Follicular 418Carcinoma, Renal Cell 412Head and Neck Neoplasms 408Glioblastoma 380Lymphoma, Large B-Cell, Diffuse 379Brain Neoplasms 376Hodgkin Disease 354Carcinoma, Hepatocellular 333Squamous Cell Carcinoma of Head and Neck 326Lymphoma, Mantle-Cell 306Sarcoma 286

Interventions

Adalimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Mucopolysaccharidosis II × Clear all
NCT02437253 2017-09-15

Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Phase 1/2 Completed
2 enrolled 10 charts

Inflammation, Mucopolysaccharidosis I, Mucopolysaccharidoses, Mucopolysaccharidosis VI, Mucopolysaccharidosis II

Data powered by HemOnc (CC BY 4.0) Colophon âš¡